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Abstract
Leupaxin is a LIM-domain containing adapter protein belonging to the paxillin family that has been
previously reported to be preferentially expressed in hematopoeitic cells. Herein, we identified
leupaxin in a screen for FAK binding partners in aortic smooth muscle, show that leupaxin is enriched
in human and mouse vascular smooth muscle, and that leupaxin expression is dynamically regulated
during development. In addition, our studies reveal that leupaxin can undergo cytoplasmic/nuclear
shuttling and functions as an SRF-cofactor in the nucleus. We found that leupaxin forms a complex
with SRF, associates with CArG-containing regions of SM promoters, and that ectopic expression
of leupaxin induces SM marker gene expression in both 10T1/2 cells and rat aortic smooth muscle
cells (SMC). Subsequent studies indicated that enhanced FAK activity (induced by fibronectin or
expression of constitutively active FAK) attenuates the nuclear accumulation of leupaxin and limits
the ability of leupaxin to enhance SRF-dependent gene transcription. Thus, these studies indicate
that modulation of the sub-cellular localization of SRF-cofactors is one mechanism by which
extracellular matrix-dependent signals might regulate phenotypic switching of SMC.
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Introduction
Mature medial SMC express high levels of the SMC differentiation marker genes (ie. myosin
heavy chain (SM-MHC), SM α-actin, SM22α among others) that contribute to the regulation
of SMC contractility 1. Unlike cardiac and skeletal muscle, SMC never terminally differentiate
and can transition to a synthetic phenotype characterized by decreased SMC marker gene
expression, increased matrix production, and responsiveness to pro-growth and migratory
signals. This unique plasticity is critical for proper vessel development, blood pressure
homeostasis, and injury repair, but can also contribute to the development of various vascular
pathologies 1. Thus, defining the signaling mechanisms that regulate SMC growth and
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differentiation will be important for understanding the processes that modulate vascular
development and is critical for the design of agents that might regulate aberrant SMC responses
in diseased vessels.
The transcription mechanisms that regulate SMC differentiation are starting to become clear.
Serum response factor (SRF) binding to conserved CArG (CC(A/T)6GG) promoter elements
is required for the expression of most SMC differentiation marker genes. It is well known that
SRF activity is regulated through interactions with additional ubiquitous and cell-type-
selective transcription factors or co-factors including the ternary complex factors (Elk-1, Sap-1,
SAP-2/NET/ERP) the GATA factors, Nkx2.5, and the LIM domain proteins CRP1, CRP2, and
FHL2 1. The myocardin factors (myocardin, MRTF-A, and MRTF-B) are particularly potent
activators of SRF-dependent transcription 2-4. Their importance in the regulation of SMC
differentiation is underscored by the lethal defects in SMC differentiation observed in
myocardin-/- and MRTF-B-/- mice 5,6. The presence of multiple co-factors likely provides the
opportunity for precise transcriptional control of the numerous SRF target genes that are known
to regulate SMC growth, migration, and differentiation.
TGF-β, which promotes SMC differentiation 7,8, and PDGF-BB, which promotes phenotypic
modulation, are important extrinsic regulators of SMC phenotype and genetic ablation of these
genes resulted in defective vasculogenesis 9,10. In addition to these soluble factors, extracellular
matrix (ECM) molecules also regulate SMC phenotype. Deletion of either FN, the α5 integrin
FN receptor, or focal adhesion kinase (FAK) (the kinase that mediates α5-dependent signaling)
result in extraembryonic and embryonic vessel defects leading to lethality in the mouse from
E8.5 to E10 11-13. In vitro, FN (which is enriched in the developing vasculature) supports SMC
proliferation and limits SMC differentiation, whereas the basement membrane components
collagen type IV and laminin (which are more prominent in the mature vessel) promote SMC
differentiation 14,15. However, it is currently unclear how integrin-dependent signals interface
with the transcriptional machinery to regulate SMC phenotype.
Herein, we identified leupaxin, an understudied LIM protein in the paxillin family, as a FAK
binding partner in SMC. We found that leupaxin is particularly abundant in SMC where it
localizes both to focal adhesions and the nucleus, indicating that it may be a bi-functional
adapter protein. Indeed, we found that nuclear localized leupaxin acts as an SRF-cofactor to
enhance SMC differentiation, and that leupaxin undergoes regulated cytoplasmic-nuclear
shuttling that is dependent on FAK activity. These data highlight the possibility that extrinsic
signals can regulate the SMC gene profile by modulating the activation state of FAK and the
localization of LIM-containing SRF cofactors.
Materials and Methods
See Supplemental Data section for a complete description of the reagents, tissue samples, DNA
constructs, and general methods used for these studies.
Statistical Analysis
All promoter measurements were performed using the indicated reporter construct in parallel
with a minimal thymidine kinase (TK-Luc) promoter. Data are presented as fold levels of SM-
promoter activity over TK promoter activity (to rule out generic increases in gene transcription)
and all data represent at least three separate experiments presented as mean +/- SEM. Means
were compared by 2-tailed Students's t test or ANOVA (where indicated) and p<0.05 was
considered statistically significant as indicated by an asterisk. All other data including Western
analysis and ChIP assays are representative of at least three individual experiments.
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We identified leupaxin as a putative FAK binding partner in a yeast two-hybrid screen of an
aortic smooth muscle cell library. This finding was somewhat surprising, because leupaxin was
previously reported to be selectively expressed in lymphoid tissues as well as several cultured
hematopoetic cell lines, osteoclasts, and a bone-derived cancer cell line 16,17. However, as our
RT-PCR results demonstrate (Fig. 1A), high levels of leupaxin message were detected in
several mouse tissues including spleen, aorta, lung, and uterus, while lower levels were
observed in stomach, bladder, heart, and brain. Western analysis using a monoclonal antibody
(Ab) that is completely specific for human leupaxin yielded a similar expression pattern and
also that leupaxin runs as a doublet of approximately 45/47 kDa in some tissues (Fig 1B). Since
a single mRNA species was identified by Northern analysis (not shown), the slower migrating
form is likely due to post-translational modification. Indeed, the leupaxin mobility shift was
reversed by treatment of human aortic lysates with calf intestinal alkaline phosphatase (CIP;
Fig. 1B, bottom left). Leupaxin expression was also strong in cultured human coronary SMC
(huCSMC) (Fig 1B, bottom right) and treatment of these cells with calyculin-A induced a
mobility shift (data not shown), in further support of a phosphorylation-induced change in
motility on SDS-PAGE. Importantly, the leupaxin antibody used does not recognize its closely
related family members paxillin (68 kda) or Hic-5 (50 kDa), which are also expressed in
huCSMC (Supplemental Fig 1A).
In accordance with the expression of leupaxin in huCSMC, immunohistochemical analysis of
human aorta revealed strong leupaxin expression throughout the media as well as in the smooth
muscle layers (but not endothelium) in the microvessels within the adventitia (Fig 1C;
Supplemental Fig. 1B). Since several ECM/integrin signaling components that regulate SMC
function have been shown to be developmentally regulated, we also examined leupaxin
expression at several stages of human aortic development. Figure 1D demonstrates that
leupaxin expression was relatively low in fetal human thoracic aorta (37 wk pc) but was much
higher at P14 and in adult (55 yr), which contain more highly differentiated SMC as revealed
by higher levels of SMα-actin. Interestingly, leupaxin was expressed in a reciprocal fashion
relative to its family members, paxillin and Hic-5. Quantitative RT-PCR analysis for leupaxin
message in thoracic aorta isolated from post-natal day 4 to adult (8weeks) mice revealed a
similar striking increase in leupaxin expression in the more mature vessels (Supplemental Fig.
1C). Notably, the 8 week samples contained 6-fold higher levels of SM22 message when
compared to day 4 vessels (not shown). Collectively, these data indicate that leupaxin is
expressed strongly in SMC, and may play a previously un-recognized role during SMC
maturation.
Given the high level of leupaxin expression in huCSMC, we utilized these cells to confirm an
interaction between FAK and leupaxin. Leupaxin localizes within focal adhesions and co-
localizes with FAK in these cells (Fig 2A and Supplemental Fig 2A). In addition, a GST fusion
protein containing the entire FAK C-terminus (GST-CTII) but not GST alone strongly
precipitated endogenous leupaxin from huCSMC lysates (Fig 2B). This interaction was
subsequently confirmed in vivo by co-immunoprecipitation of a FAK-leupaxin complex from
Cos 7 cells (Fig 2C). Somewhat surprisingly, a GST fusion protein containing the more C-
terminal FAT domain of FAK (GST-CTI) efficiently precipitated paxillin but not leupaxin (Fig
2B). These results indicate that leupaxin association with FAK requires sequences N-terminal
to the FAT domain, and perhaps, that leupaxin may not directly compete with paxillin and/or
Hic-5 for FAK binding. Reciprocal mapping studies revealed that the N-terminal LD motifs
in leupaxin were sufficient to precipitate FAK from cell lysates (Fig 2D) and subsequent
deletion studies revealed that LD3 is the major site on leupaxin that directs binding to FAK
(Fig 2E and Supplemental Fig 2B).
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Interestingly, we also observed a subset of huCSMC (approximately 15% of cells maintained
in serum) that exhibited both focal adhesion and nuclear-localized leupaxin suggesting that
like several other LIM proteins, leupaxin shuttles between focal adhesion and nuclear
compartments (Fig 2A). To test this more directly, we treated huCSMC with the CRM1-
dependent nuclear export inhibitor, leptomycin B (LMB). LMB treatment for 20 min-1 hr
induced a dramatic redistribution of endogenous leupaxin to the nuclear compartment (Fig 3A-
B), while treatment for 3 h resulted in nearly complete nuclear localization (not shown).
Importantly, immunohistochemical localization of leupaxin in the media of aortic tissue
sections also revealed both nuclear and cytoplasmic staining (Fig 3B).
As noted above, several LIM domain proteins that exhibit nuclear accumulation have been
implicated in the regulation of gene transcription 18. In fact, the smooth muscle-specific LIM
proteins, CRP1 and CRP2, and the cardiac/SMC-selective LIM protein, FHL2, have been
shown to interact with SRF and to regulate SRF-dependent gene expression 19,20. To test
whether leupaxin can contribute to the regulation of transcription in SMC, we co-transfected
flag-tagged leupaxin along with SM22 or SM α-actin promoter/luciferase constructs into multi-
potential mouse 10T1/2 cells. As shown in figure 4, expression of leupaxin strongly increased
SM22 and SM α-actin promoter activity in a dose-dependent fashion and enhanced the effects
of TGF-β in this model. Expression of leupaxin also significantly up-regulated SM22 (Fig 4C)
and SM α-actin promoter activity (data not shown) in primary rat aortic SMC (rASMC). The
more modest effects of leupaxin in SMC are most likely due to the already high levels of SMC-
specific transcriptional activity in primary SMC cultures. Importantly, ectopic expression of
leupaxin in 10T1/2 cells induced the expression of endogenous SM gene transcription as
assessed by quantitative RT-PCR for SM22 (Fig 4D) and by Western analysis for SM-MHC
(the canonical smooth muscle-specific marker) and SM α-actin (Fig 4E).
We hypothesized that nuclear leupaxin, like CRP1/2, might regulate SMC-specific gene
expression by interacting with SRF. In support of this idea, leupaxin failed to activate a SM
α-actin promoter that contained mutations to all three SRF-binding CArG boxes (ABI; Fig
5A). In addition, we found a co-association of GFP-leupaxin and flag-SRF in reciprocal co-
immunoprecipitation assays performed in Cos-7 cells (Fig 5B) and that GST-leupaxin
interacted directly with 35S-labeled SRF translated in vitro (Fig 5C). We also used ChIP assays
to demonstrate that endogenous leupaxin associated with the CArG-containing regions of the
SM α-actin and SM-MHC promoters (but not with the c-fos promoter) in huCSMC grown in
serum (Fig 5D). When combined with results from gel shift assays demonstrating that leupaxin
did not associate directly with the SM α-actin CArGs (not shown), these results strongly suggest
that leupaxin interacts with SRF in vivo. Interestingly, leupaxin was not found in association
with CArG elements in serum-starved huCSMC, however under these conditions, TGF-β
significantly promoted leupaxin association with CArG-containing region of the SMα-actin
promoter, without effecting leupaxin expression levels (Fig 5E). These data corroborate the
finding that leupaxin and TGF-β exhibit functional synergy in the promotion of SM marker
gene expression. To directly test whether the effects of leupaxin on SMC differentiation marker
gene required SRF, we expressed leupaxin in SRF-/- ES cells. As expected, expression of
leupaxin did not enhance SM22 reporter gene expression in SRF -/- ES cells but this response
could be rescued by co-expression of SRF (Supplemental Fig 3). Collectively, these data
strongly support our hypothesis that leupaxin is recruited to the SMC-specific promoters
through a direct interaction with SRF and that this leads to increased SMC differentiation
marker gene expression.
Our next goal was to test whether leupaxin nuclear/cytoplasmic shuttling was an important
mechanism that regulated leupaxin's effects on SMC-specific transcription. The effects of LMB
indicated that leupaxin likely contains a leucine-rich CRM-1-dependent nuclear export
sequence (NES), and we identified two regions (aa 4-11 and aa 134-144) that conformed to
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consensus NES sequences identified in the LIM proteins, Trip6, Zyxin, LPP and Hic-5 (Fig
6A) 21. Four leucine to alanine mutations were made at each site (mNES1; L4,7,8,11 A and
mNES2; L134,137,141,144A) separately and in combination (dbl-mNES) in the context of GFP-
leupaxin. We utilized 10T1/2 cells and rat primary aortic SMC (rASMC) for these and
subsequent localization experiments since the huCSMC proved to be remarkably resistant to
transfection. Importantly, significant leupaxin mRNA is expressed in both 10T1/2 and rASMC
(not shown), and the sub-cellular localization of GFP-leupaxin in these cells was virtually
identical to that of flag-leupaxin and to the localization of endogenous leupaxin in huCSMC.
(Fig 6A). Similar to our previous results, 15% of 10T1/2 cells exhibited nuclear accumulation
of GFP-leupaxin while treatment with LMB for 1 h resulted in nuclear accumulation in nearly
all cells (Fig 6A). While individual mutation of either NES1 or NES2 increased the percentage
of cells with nuclear GFP-leupaxin (to approximately 45%), mutation of both sites resulted in
nuclear localization in approximately 90% of transfected cells (Fig 6A and Supplemental Fig
4A). Similar results were observed in rASMC (not shown). Importantly, transfection of these
constructs did not significantly affect cell morphology (Supplemental Fig 4B). These data
provide strong evidence to support that leupaxin undergoes Crm-1 dependent export, and that
the NES sequences identified are important for the rapid shuttling of leupaxin from the nucleus
to the cytoplasm.
Although the dbl mNES variant did exhibit nuclear-restricted expression, this construct
contains disrupted LD1 and LD4 binding motifs that could affect normal leupaxin function.
Thus to directly test the effects of nuclear localization on transcriptional activity we generated
a leupaxin variant that was targeted to the nucleus by fusion of a triple NLS tag to the N-
terminus of wild type leupaxin. This construct exhibited nearly complete nuclear localization
in 100% of transfected 10T1/2 cells (Fig 6A) and SMC (data not shown) and was functional
as shown by its ability to activate the SM22 promoter even more strongly than Wt leupaxin
(Fig 6B). These data strongly support the idea that leupaxin's ability to induce gene expression
is dependent on nuclear not focal adhesion localization. Furthermore, these data suggest that
leupaxin's function as a transcriptional regulator can be modified by altering it's subcellular
localization.
Our demonstration of a FAK-leupaxin interaction suggested that FAK may regulate leupaxin
localization and/or transcriptional activity. We reasoned that enhanced FAK activity might
lead to sequestration of leupaxin in focal adhesions, thus limiting its effects in the nucleus. To
test this hypothesis, we examined endogenous leupaxin localization in huCSMC under
different conditions that modulate FAK activity. huCSMC plated on tissue-culture plastic
under serum-starved conditions exhibit low FAK activity (as assessed by auto-phosphorylation
of FAK on Y397) and near complete restriction of leupaxin within the nucleus (Fig 7A, B).
Interestingly, in serum-starved cells plated on FN for 90 min (that exhibit high FAK activity),
leupaxin was exclusively associated with focal adhesions (Fig 7A). We next used a
pharmacological approach to determine whether endogenous leupaxin shuttling was regulated
by FAK/Src activity. We found that treatment with FAK/Src inhibitor, PP2, attenuated FAK
activity and lead to remarkable nuclear accumulation of leupaxin in huCSMC plated on FN
(Fig 7A-B).
We next utilized the GFP-tagged leupaxin construct to track leupaxin shuttling in real time in
transfected SMC to determine whether FAK/Src activity regulates the rate of leupaxin
translocation to the nucleus. To this end, we identified cells in which GFP-leupaxin was
predominantly cytoplasmic, pre-treated the cells with PP2 or vehicle for 10 min and then
performed time-lapse imaging immediately following LMB treatment. LMB-induced leupaxin
nuclear accumulation was evident much earlier in PP2-treated SMC compared to vehicle-
treated cells (Fig 7C; Online movies 1 and 2). Indeed, 90% of PP2 pre-treated cells exhibited
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marked leupaxin nuclear localization within 5 min following LMB treatment, while vehicle-
treated cells required at least 20 min to exhibit significant nuclear accumulation.
In support of a functional significance of FAK-dependent leupaxin shuttling, we found that
overexpression of a constitutively active FAK variant (termed SuperFAK; 22, promoted focal
adhesion-associated leupaxin localization (similar to plating on FN) and partially reversed the
marked leupaxin-induced SMC-marker gene transcription in 10T1/2 cells (Fig 7D). It should
be noted that although both ectopic expression of SuperFAK (data not shown) and plating cells
on FN resulted in pronounced focal adhesion localization in cells maintained in 10% serum,
treatment of both populations of cells with LMB for 1 hr did result in substantial nuclear
accumulation of leupaxin. Thus, even under conditions of enhanced FAK activity some nuclear
shuttling of leupaxin does occur, which may (in part) account for the incomplete rescue of
promoter activity observed following SuperFAK expression. Taken together, these results
indicate that activation of FAK inhibits leupaxin-induced transcription by sequestering
leupaxin to focal adhesions.
Discussion
Leupaxin is an understudied 43 kDa protein that was originally reported as having a lymphoid-
restricted expression pattern 16. We show for the first time that leupaxin is also highly expressed
in aorta and in cultured SMC. In addition, our studies reveal that leupaxin can undergo
cytoplasmic/nuclear shuttling and functions as an SRF-cofactor in the nucleus. We found that
leupaxin forms a complex with SRF, associates with CArG-containing regions of the SMC-
specific promoters, and that ectopic expression of leupaxin induces SMC differentiation marker
gene expression. Subsequent studies indicated that enhanced FAK activity attenuates the
nuclear accumulation of leupaxin and limits the ability of leupaxin to enhance SRF-dependent
gene transcription. Thus, these studies indicate that sequestration of leupaxin to focal adhesion
plaques may be one mechanism by which ECM-dependent signals might regulate phenotypic
switching of SMC.
Leupaxin belongs to a family of proteins including paxillin and Hic-5 that may share some
overlapping cellular functions. Each of these proteins are comprised of four N-terminal LD
motifs and four C-terminal LIM domains 21 and they share approximately 40% identity at the
amino acid level. Leupaxin has also been reported to share several binding partners with
paxillin such as Pyk2, FAK, Src, PTP-PEST and p95 paxillin kinase linker 16,17,23,24. Leupaxin
was previously shown to co-localize with Pyk2 and FAK in the cortical F-actin domain in JY8
lymphoblasts and within podosomes of osteoclasts 16,23. Thus far, known functions for
leupaxin include suppression of B-cell antigen receptor signaling in lymphoblasts 25, induction
of bone resorption in osteoclasts 24, and induction of cell motility in bone-derived prostate
cancer cells 17.
Treatment with the nuclear export inhibitor, leptomycin B causes retention of paxillin, Hic-5,
and leupaxin in the nucleus, providing evidence that each of these family members may share
a common function to coordinate cell adhesion status with specific changes in gene expression
21. While numerous LIM proteins have been shown to undergo nucleo-cytoplasmic shuttling,
it is becoming clear that distinct mechanisms regulate their trafficking. Hic-5 demonstrates
oxidant-sensitive nuclear export that was shown to be dependent on two cysteine residues
located proximal to the canonical NES identified within the Hic-5 LD3 motif 26. Notably, Hic-5
appears to be unique in this regulation as neither paxillin nor leupaxin harbor similarly located
cysteine residues. Recently, elegant studies by Tsujita et. al. indicate that nuclear shuttling of
zyxin in cardiomyocytes is regulated in a cGMP and AKT-dependent fashion and that agonists
that stimulate PKG (including estradiol and IGF-1) induce dramatic nuclear accumulation of
zyxin and paxillin in these cells 27. On the other hand, the LIM only protein FHL2 has been
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shown to translocate to the nucleus in response to Rho A-dependent signals 28. While we have
not observed Rho- or cGMP-dependent nuclear accumulation of leupaxin in huCSMC in these
studies (not shown), we did find that leupaxin localization was regulated by the activation state
of FAK in these cells. Interestingly, leupaxin was recently shown to be a substrate for Src in
A20 B lymphoma cells 25 and we have shown that leupaxin is a direct substrate for FAK in
vitro (unpublished data). Thus, we favor a model whereby activation of FAK and/or Src likely
promotes phospho-tyrosine-dependent leupaxin protein interactions within focal adhesions,
thus limiting the amount of leupaxin available to shuttle to the nucleus. It remains to be
determined whether FAK activity may also regulate SM gene expression through cytoplasmic
retention of other LIM-containing SRF co-factors.
Once in the nucleus, LIM proteins can participate in transcriptional control, a function likely
dependent on the ability of these proteins to provide scaffolds for transcription factors and/or
chromatin remodeling factors. Both paxillin and Hic-5 bind to steroid receptors and have been
shown to co-activate androgen, glucocorticoid, and progesterone response genes by bridging
an association with the nuclear matrix 29,30. In addition, Hic-5 has been shown to influence
Sp1-dependent c-fos and p21 expression by inducing a complex between Sp1, SMAD3, and
the histone acetyltransferase, p300 31. The finding that Hic-5 and leupaxin appear to be
reciprocally expressed during development (with higher levels of Hic-5 observed in less
differentiated SMC) coupled with evidence that Hic-5 regulates Sp1-dependent transcription,
while leupaxin regulates SRF-dependent transcription, is particularly interesting with respect
to SMC phenotypic switching. Although Sp1 can act as either a transcription enhancer in certain
cell types, in SMC, Sp1 acts as a repressor of SMC marker gene transcription by interacting
with G/C rich repressor elements contained in SM22 and SM-MHC promoters 32. Thus, it is
possible that these two FAK binding partners have opposing functions with respect to SM gene
transcription.
Although the paxillin family members may induce divergent gene regulation in SMC, several
other LIM domain proteins besides leupaxin including CRP1/2, LPP, and FHL2 (which also
cycle between focal adhesions and the nucleus) share the ability to influence SRF-mediated
gene transcription 19,20,33. Although some of these LIM proteins may have partially
overlapping functions, it is likely that additional regulatory pathways that alter the expression
levels, localization, or protein binding interactions ultimately impart specific functions for each
of these molecules.
In conclusion, we propose a model that leupaxin may play a dual role in SM function; aiding
to coordinate multi-protein complexes in focal adhesions and in the nucleus. Since leupaxin
localization is clearly modulated by FAK/Src activity in SMC, we postulate that ECM- and
agonist-dependent regulation of FAK activity in vessels could impart precise control of
leupaxin localization in order to balance the migratory and contractile capacities necessary for
proper vasculogenesis during development and following vascular injury. Interestingly, recent
studies in our laboratory indicate that FAK inactivation in SMC by homologous recombination
promotes TGF-β induced SMC differentiation but attenuates PDGF-stimulated SMC motility
(unpublished observaitons). Thus, it will be of future interest to determine to what extent these
phenotypes are due to mis-localization of leupaxin. Although our data provide clear evidence
of a role for nuclear leupaxin in promoting SRF-dependent gene transcription, future gene
targeting studies will be necessary to determine under which circumstances leupaxin activity
might be necessary for specific SMC functions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Leupaxin is expressed at high levels in arterial and visceral smooth muscle
A. Leupaxin qRT-PCR was performed on adult mouse tissue. Data are represented as relative
to 18S RNA control. B (top) Western analysis for leupaxin in adult human tissues (46-60 yrs;
50 μg each) including spleen (Spl), heart (H), stomach (St), uterus (UT), and aorta (Ao) (bottom
left) Human aorta lysate was incubated in the presence (+) or absence (−) of calf intestinal
alkaline phosphatase (10 units) for 20 min at 30°C. (bottom right) Levels of leupaxin in
huCSMC compared to spleen. ERK is shown as a loading control C. Immunohistochemical
staining for leupaxin and SMα-actin in human aorta (37 week pc) detected by DAB (brown)
and counter-stained with methyl green. D. Western analysis of human thoracic aorta from fetal
(37 week pc), neonatal (2 wk post-natal), and adult (55 yrs). ERK levels are shown as a loading
control.
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Figure 2. Leupaxin associates with FAK in huCSMC
A HuCSMC cultured in 10% serum were co-stained with anti-leupaxin Ab, phalloidin, and
DAPI (40 X) B. huCSMC lysates were incubated with GST or GST-FAK C-terminal fusion
proteins (GST-CTI or GST-CTII) prior to Western analysis for paxillin (Pax) or leupaxin (Leu).
C. GFP-tagged leupaxin was co-expressed in Cos7 cells with or without Flag-tagged FAK and
immunoprecipitations (IP) with anti-Flag antibody were performed followed by
immunoblotting with indicated antibodies. A 10% loading control (LC) is shown. D. Cos7
expressing Flag-FAK were incubated with GST or GST-Leu (full-length) or a N-terminal
leupaxin fusion protein containing LD motifs 1-4 (GST-LD1-4) prior to Western analysis for
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FAK. E. Cos7 expressing GFP-Leupaxin variants with individual deletions of LD motifs 1-4
were incubated with GST or GST-CTII prior to Western analysis for GFP.
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Figure 3. Leupaxin localizes within focal adhesions and the nucleus and undergoes Crm-1/exportin-
dependent nuclear-cytoplasmic shuttling
A,B. huCSMC cultured in 10% serum were treated with or without Leptomycin B (LMB; 5ng/
ml) for indicated times prior to fixation. Cells were co-stained with anti-leupaxin Ab,
phalloidin, and DAPI (40 X) and cells were scored for nuclear accumulation. Data represent
3 separate experiments (150-200 cells/time point) B. Subcellular localization of leupaxin or
SMα-actin detected by DAB (brown) staining in medial smooth muscle. Sections were counter-
stained with methyl green to demarcate the nuclei. Flag antibody was used for the IgG control
(left panel). Black and red arrows demarcate nuclear and cytoplasmic leupaxin staining
respectively.
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Figure 4. Ectopic expression of leupaxin stimulates SM marker gene transcription
A,B. 10T1/2 cells were co-transfected with the SM22- or SMα-actin luciferase constructs and
Flag-leupaxin (Leu). Total DNA was normalized with empty vector, EV). Cells were serum
starved (0.5% serum) for 24 hrs prior to treatment with vehicle or TGF-β (1ng/ml) overnight
and luciferase activity was measured. The * indicates p<0.05 between groups (analyzed by
ANOVA). C. Promoter-reporter assays in rASMC maintained in 10% serum measured 48 hrs
following transfection. D, E Quantitiative RT-PCR for SM22 (D) or Western blot (E) of SMC
(5 μg) or 10T1/2 cells (25 μg) transfected with EV or Leu for 48hrs under serum-starved
conditions (0.5% serum). ERK is shown as a loading control.
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Figure 5. Leupaxin interacts with SRF and induces SRF- and CArG-dependent gene transcription
A. Promoter-reporter assay in rASMC using the SMα-actin promoter or a triple CArG mutant
SM α-actin promoter (ABI Mutant) B. Cos7 cells were transfected with Flag-SRF and GFP-
leupaxin or GFP and immunoprecipitation and Western analysis was performed with the
indicated antibodies. A 10% lysate is shown as a loading control (LC). C. Pull-down assays
using GST or GST-leupaxin with 35S labeled in vitro translated SRF. Complexes were
electrophoresed and processed for autoradiography. 2% of the total 35S-SRF used is shown as
a loading control. D,E. ChIP was performed on huCSMC grown in 10% serum (D) or serum
starved (no serum) for 36 hr and treated with vehicle or TGF-β for 18 hr (E) using the indicated
antibodies and primers. (bottom) Western analysis for leupaxin in vehicle and TGF-β treated
huCSMC.
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Figure 6. Regulation and function of nuclear-targeted leupaxin
A (top) Schematic of leupaxin structure with alignment of assumptive NES1 and 2.
(middle) GFP-leupaxin or GFP-leupaxin with both NES mutations (dbl-mNES) were
transfected into 10T1/2 cells. Where indicated LMB was added 1 hr before fixation.
(bottom) Quantification of nuclear leupaxin accumulation. Data represent at least 150 cells
per condition collected from 3 separate experiments. B. Promoter-reporter assay in 10T1/2
cells transfected with increasing concentrations of Leu and NLS-Leu. Western blot reveals
comparable expression levels of the two proteins.
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Figure 7. FAK activity modulates leupaxin localization and function
A,B serum-starved (no serum) huCSMC were plated on plastic (SFM) or fibronectin (FN) for
90 min in absence or presence of PP2 (10 μM) for the last 30 min. Cells were processed for
immunocytochemistry (A) or Western analysis (B) using a phosporylation-site specific
Y397FAK Ab or an antibody that recognizes total FAK levels. C. GFP-leupaxin expressing
rASMC were pre-treated with vehicle or PP2 (10 μM) for 10 min prior to treatment with LMB
at time 0 (T0). Fluorescent images were captured for 30 minutes (see Online Movies 1 and 2).
Images shown are representative of 10 time-lapse movies for each condition. D. Λεφτ:
Πρoμoτερ–ρεπoρτερ ασσαΨσ ιν 10T1/2 χελλσ εξπρεσσινγ Λευ ανδ/oρ Φλαγ–ΣυπερΦAK
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(ΣΦAK; 0.25μg each). Right: Western blot indicates levels of Flag-Leu, SFAK, and FAK
activity.
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